Navigation Links
Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
Date:5/13/2008

ng the risk that study or clinical trial results may require Jazz Pharmaceuticals to discontinue the development of one or more product candidates; risks related to the uncertain and time-consuming regulatory approval process; and risks relating to the need for additional funds. These and other risk factors are discussed under "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2007 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on March 31, 2008. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

JAZZ PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)

Three Months Ended March 31,

2008 2007

Revenues:

Product sales, net $13,984 $11,625

Royalties, net 365 211

Contract revenues 285 2,252

Total revenues 14,634 14,088

Operating expenses:

Cost of product sales (excluding

amortization of acquired developed

technology) 2,298 2,003

Research and development 21,243 14,867

Selling, general and administrative 32,780 14,339

Amortization of intangible assets 2,121 2,362

Total operating expenses 58,442 33,571

Loss from operations
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medimetriks Pharmaceuticals, Inc. Begins Operations
2. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
3. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
5. Jazz Pharmaceuticals, Inc. to Announce First Quarter Results on May 13, 2008
6. Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
7. Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition
8. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
9. Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
10. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
11. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
(Date:12/22/2014)... 22, 2014  Alternative Energy & Environmental Solutions, ... signed a letter of intent to acquire BioTechPharma ... patented a nanotechnology-based development platform used to create ... rapid on-site collection and testing to identify infectious ... in an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... Magellan Biosciences, a global manufacturer of products designed ... labor intensive, announced that its Vice President of Business ... featured speaker at the Medicaid Health Plans of America ... takes place tomorrow in Washington, DC. Mr. De Jesus ...
... 17, 2011 Anaphore Inc. today announced that Katherine Bowdish, ... overview at the 13th Annual C21 BioVentures conference. The presentation ... at The Meritage Resort in Napa, Calif.   ... is developing a new class of protein pharmaceuticals to address ...
... PERTH, Australia, May 17, 2011 Australian supplier of ... an exclusive distributor agreement with a leading Japanese Life ... Taiwan, China and South Korea. Headquartered in ... in the chemical, pharmaceutical and biotechnology industries and have ...
Cached Biology Technology:Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum 2Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum 3Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum 4Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum 5Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum 6Anaphore to Present Company Overview with Focus on Atrimer Technology Platform at 13th Annual C21 BioVentures Conference 2Epichem and AR Brown Sign Exclusive Distribution Agreement for Japan, Taiwan, China and South Korea 2Epichem and AR Brown Sign Exclusive Distribution Agreement for Japan, Taiwan, China and South Korea 3
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
(Date:12/3/2014)... Dec. 2, 2014 As part of our ... Technologies is pleased to announce the release of a ... to collect the workforce data that they need. ... been left by existing readers. Many such devices have ... and modern technology. Older models force users to navigate ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2
... COLUMBIA, Mo. Studies show the incidence of diabetes in ... Now, University of Missouri veterinarians have changed the way veterinarians ... monitor glucose in humans. Dogs are susceptible to type ... in their bloodstream because their bodies do not produce enough ...
... is often referred to as the land of opportunity. ... of opportunity." NJIT gave him the opportunity, for instance, ... distinguished professor in the department of physics. Naqvi started the ... his research recently helped him win a Goldwater Scholarship ...
... Ohio Mosquitoes make proteins to help them handle the ... blood meals, a new study has found. The mosquito,s ... finding warm-blooded hosts, avoiding detection, penetrating tough skin and evading ... a human hand. Until now, the stress of the ...
Cached Biology News:MU researchers pioneer animal diabetes treatment 2Third brother wins gold at NJIT 2Study shows how mosquitoes handle the heat of a hot blood meal 2Study shows how mosquitoes handle the heat of a hot blood meal 3
... product has been developed to significantly increase ... proteins. Stability is increased at room ... centigrade. This product is subjected to ... or azide. This formulation insures consistently ...
This unique buffer provides a gentle method for removal of primary and secondary antibodies to allow several reprobings on the same membrane. Gentle buffer will not alter the antigen for subsequent i...
... The 500 optimization kit is for fine-tuning ... interest. The kit is recommended when you ... system. The kit includes 0.25 g each ... micrometer diameter gold microcarriers, 100 each of ...
... Serial Analysis of Gene Expression (SAGE) ... technology. Agencourt offers a cost-effective outsourcing ... and LongSAGE libraries. Agencourt's SAGE sequencing ... project turnaround and long Phred20 read ...
Biology Products: